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this research team (DR) collected the 
eggs from the hair shaft, they were 
found ≈3 3.5 cm from the hair fol-
licle. Because hair grows ≈1.25 cm per 
month, the louse infestation occurred 
≈3 months before egg collection (6).
Homeless persons that we have 
monitored for many years are often 
heavily infested by body lice but are 
also occasionally infested with head 
lice. Before genetic tools that differen-
tiate the head and body louse lineages 
were available (5), it was speculated 
that body lice may have originated 
from head lice (9). From our study, it is 
clear that under conditions of massive 
infestation, body lice can migrate and 
colonize hair; the opposite may also be 
true. However, there is no evidence that 
body lice are capable of causing an out-
break of lice living on the head, as hap-
pens among schoolchildren that have 
been found to be infested only by head 
lice. This suggests that body lice can-
not thrive in the environment of head 
lice, which infest millions of children 
worldwide (10), further suggesting 
that outbreaks of trench fever are most 
likely not linked to head lice in indus-
trialized countries. In conclusion, by 
analyzing lice harvested from the heads 
and clothing of homeless persons, we 
have shown that the 2 ecotypes belong 
to the same body lice population.
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Acute Hepatitis E 
Infection in  
Immunocompetent 
Woman
To the Editor: Hepatitis E vi-
rus (HEV) is a common cause of 
acute hepatitis in developing coun-
tries. The course of acute hepatitis E 
is usually benign, except in pregnant 
women and in immunocompromised 
patients, who are prone to a lethal or 
chronic outcome of the disease. Since 
2001, hepatitis E has been emerg-
ing in industrialized countries, and 
neurologic manifestations such as 
Guillain-Barré syndrome, brachial 
neuritis, transverse myelitis, and cra-
nial nerve palsies have been reported 
in patients with acute or chronic forms 
of the disease (1–6). Most cases with 
neurologic manifestations have been 
characterized by infection with geno-
type 3 HEV. Data are not available to 
indicate whether this association be-
tween HEV infection and neurologic 
manifestations is related to a specific 
antigenic stimulus provided by HEV 
or is linked to the more comprehen-
sive assessment for such neurologic 
conditions that is available in industri-
alized countries or to a reporting bias. 
We report a case of HEV infection in 
an immunocompetent woman who 
had muscle-specific kinase (MuSK) 
antibody–positive myasthenia gravis 
associated with HEV replication.
A 33-year-old woman was hos-
pitalized in France for subacute as-
thenia and intermittent symptoms 
including dysarthria, dysphagia, 
muscle weakness, and diplopia. She 
had no family history of autoimmune 
disease and no notable personal 
medical history; she had not received 
any recent vaccinations and had not 
traveled outside France during the 
previous year. Physical examination 
showed no pyramidal, vestibular, or 
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cerebellar syndromes, and all tendon 
reflexes were typical.
On admission, the patient’s liver 
function tests showed elevated ala-
nine transaminase (190 UI/L). Test re-
sults were within reference ranges for 
aspartate aminotransferase, alkaline 
phosphatase, gamma-glutamyl trans-
peptidase, and creatine kinase levels. 
Antibody tests were negative for hepa-
titis B virus, hepatitis C virus, HIV, 
human T-lymphotropic viruses 1 and 
2, and Treponema pallidum, but test-
ing for cytomegalovirus and Epstein-
Barr virus showed previous exposure. 
Serum samples were positive for HEV 
IgM (index 11) and negative for HEV 
IgG (index 0.71) by Adaltis microplate 
ELISA (EIAgen; Adaltis, Casalecchio 
Di Reno, Italy). HEV RNA was detect-
ed in serum and fecal samples by using 
HEV reverse transcription PCR (RT-
PCR) (Ceeram, La Chapelle sur Erdre, 
France) on the SmartCycler II instru-
ment (Cepheid, Sunnyvale, CA, USA). 
Sequencing studies showed that the 
HEV strain belonged to genotype 3f.
Brain magnetic resonance imag-
ing results were normal, and results for 
analysis of cerebrospinal fluid were 
normal (leukocytes <5 cells/µL, glu-
cose 3.2 mmol/L, protein 38 mg/dL, 
HEV RT-PCR negative). A nerve con-
duction study, performed even though 
the patient was not symptomatic, did 
not find any abnormality. Pharmaco-
logic testing with prostigmine (0.5 
mg intravenously) did not result in 
symptom improvement. Computed 
tomography scan of the mediastinum 
showed no thymoma. Test results for 
anti-acetylcholine receptor antibodies 
were negative; however, results were 
positive for MuSK antibodies (18.7 
U/mL by radioimmunoassay; RSR 
Ltd., Cardiff, Wales, UK). These data, 
combined with physical examination, 
confirmed the diagnosis of myasthe-
nia gravis.
Given this association of myas-
thenia and acute HEV infection, we 
suspected the potent role of HEV in-
fection in the neurologic symptoms. 
Therapy was started with ribavirin 
(1,000 mg/day for 1 month) and intra-
venous immunoglobulin (IVIG) (1 g/
kg/d for 2 days). Alanine transaminase 
levels rapidly decreased, and after 3 
months, test results for HEV IgM and 
HEV RT-PCR in serum were negative. 
IVIG treatment relieved symptoms 
in the short term, but symptoms re-
turned 15 days after treatment ended, 
requiring continuation of IVIG every 
4 weeks for 6 months. Four months 
after the last infusion of IVIG, the 
patient reported mild 4-limb fatiga-
bility after exercise, but results of ob-
jective neurologic examination were 
normal. Results for MuSK antibodies 
were still positive, and treatment with 
azathioprine (150 mg/d) was started. 
Three weeks later, the patient required 
another infusion of IVIG for difficulty 
in swallowing, dyspnea, and 4-limb 
weakness, but she was free of symp-
toms for the remaining 5 months of 
follow-up.
In conclusion, we describe a case 
of anti-MuSK myasthenia gravis as-
sociated with acute HEV in a young, 
immunocompetent patient in France. 
Because myasthenia gravis with 
MuSK antibodies is rare (≈10% of 
myasthenia gravis cases) (7), the po-
tential role of HEV infection as a trig-
ger of autoimmune disorders should 
be investigated. Some cases of anti-
MuSK myasthenia gravis associated 
with HIV (8) or Epstein-Barr virus (9) 
infections have been reported. Never-
theless, our findings do not enable us 
to draw conclusions regarding causal-
ity. Our observation might suggest a 
coincidental temporal association be-
tween HEV infection and myasthenia 
gravis or a triggering of autoimmunity 
by HEV. Moreover, anti-MuSK myas-
thenia gravis is usually characterized 
by a rapidly progressive course with 
moderate to severe symptoms (7). The 
initial unusually benign clinical course 
in this patient might be explained by 
the effect of early ribavirin treatment 
or, more likely, by a particular type of 
MuSK antibodies (10).
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To the Editor: Mulvey et al. (1) re-
ported the emergence of ciprofloxacin 
resistance in Salmonella enterica se-
rovar Kentucky of multilocus sequence 
type 198 (ST198) in Canada (1). Cip-
rofloxacin resistance in S. enterica ser. 
Kentucky was reported in 2011 in pa-
tients from Europe, most of whom had 
traveled to Africa and the Middle East 
(2). Since then, S. enterica ser. Ken-
tucky ST198 with additional resistance 
to third-generation cephalosporins and 
carbapenems has been reported from 
France and Morocco, again associ-
ated with travel (3). Poultry has been 
implicated as the most likely vehicle for 
infection by this sequence type (2,3). 
Resistance to third-generation cephalo-
sporins and carbapenems has not been 
seen in North America; however, the 
emergence of ciprofloxacin-resistant 
infections has been observed (1). 
In the United States, S. enterica 
ser. Kentucky is the most common se-
rotype isolated from chickens and the 
second most common found among 
retail chicken, but ciprofloxacin resis-
tance has not been documented among 
these sources (4). We sought to deter-
mine if ciprofloxacin- or ceftriaxone-
resistant S. enterica ser. Kentucky 
has emerged in humans in the United 
States. We examined isolates and data 
from the National Antimicrobial Re-
sistance Monitoring System to docu-
ment antimicrobial resistance and se-
quence type and to assess possible risk 
factors for acquiring infection.
Participating state and local 
public health laboratories submit 
every 20th nontyphoidal Salmo-
nella (NTS) isolate to the Centers 
for Disease Control and Prevention 
for susceptibility testing. MICs of 
>15 antimicrobial agents were deter-
mined by using broth microdilution 
(Sensititer, Cleveland, OH, USA) 
according to the manufacturer’s in-
structions. Where available, Clinical 
and Laboratory Standards Institute 
performance standards were used for 
interpretation of MICs; otherwise, 
interpretations established by the 
National Antimicrobial Resistance 
Monitoring System were used (5,6).
During 2009–2012, a total of 
21 (0.2%) of the 9,225 NTS isolates 
tested were S. enterica ser. Kentucky. 
Six (29%) were resistant to ciprofloxa-
cin; all were susceptible to ceftriaxone 
(Table) (5). As was observed in Cana-
da, the 6 resistant isolates were >80% 
similar by pulsed-field gel electropho-
resis analysis (XbaI; data not shown), 
and all 6 were ST198. Although a rare 
cause of human infection, S. enterica 
ser. Kentucky represented 23% (6/26) 
of all ciprofloxacin-resistant NTS de-
tected during 2009–2012. 
The median age of the 6 patients 
with ciprofloxacin-resistant S. enteri-
ca ser. Kentucky infections was 32 
years (range 9 months–56 years); 5 
(83%) were female. Of the 4 patients 
for whom information was available, 
2 were hospitalized, and 1 died. Spec-
imen sources were stool (n = 3) and 
urine (n = 3). Travel histories were 
obtained for 5 patients, and all had 
traveled internationally in the 7 days 
before specimen submission: 2 were 
residents of other countries (Saudi 
Arabia and Ethiopia), and 3 were 
US residents who had returned from 
travel to India. By comparison, only 
3 of 10 patients with ciprofloxacin-
susceptible infections had traveled 
(p = 0.02).
Resistance to ciprofloxacin in Sal-
monella is a growing concern because 
it limits treatment options for invasive 
disease. We describe ciprofloxacin-
resistant S. enterica ser. Kentucky 
isolated from 6 patients in the United 
States. The emerging global story of S. 
enterica ser. Kentucky ST198 demon-
strates the need for international inte-














type Antimicrobial resistance† 
AM41047 <1/F Black Ethiopia 2009 Stool AMP,	FIS,	GEN,	NAL,	STR,	TET 
AM45820 54/F Unknown Unknown 2010 Urine AMP,	COT,	FIS,	GEN,	NAL,	STR,	TET 
AM47052 56/F Asian India 2011 Urine AMP,	FIS,	GEN,	NAL,	STR,	TET 
2012AM-1081 2/F Asian India 2012 Stool AMP,	NAL 
AM50773 37/M Asian India 2012 Stool AMP,	AUG,	FIS,	GEN,	NAL,	STR,	TET 
2012AM-0353 42/F White Saudi	Arabia 2012 Urine AMP,	FIS,	FOX,	KAN,	NAL,	STR,	TET 
*ID,	identification;	AMP,	ampicillin;	AUG,	amoxicillin-clavulanic acid;	COT,	trimethoprim-sulfamethoxazole;	FIS,	sulfisoxazole;	FOX,	cefoxitin;	GEN,	
gentamicin;	KAN,	kanamycin;	NAL,	nalidixic	acid;	STR,	streptomycin;	TET,	tetracycline. 
†Resistance of isolate from infected patient to antimicrobial agents other than ciprofloxacin. 
 
